Motility & Functional GI · Article 125

Which Treatments Actually Work for Functional Dyspepsia?

Functional dyspepsia treatment requires a structured, evidence-based clinical approach. This review summarizes the key diagnostic, management, monitoring and decision points for gastroenterology and hepatology practice.

Functional dyspepsia treatment clinical reference — Related free clinical resource: Clinical Pharmacology.

Functional dyspepsia treatment: practical clinical approach

This page focuses on Functional dyspepsia treatment with emphasis on decisions that change patient care, common pitfalls, and the current evidence base.

External guidance for Functional dyspepsia treatment

Clinical takeaway: For Functional dyspepsia treatment, decisions should integrate current guidelines, patient-specific risk, and the evidence summarized below.

Answer first: Evidence-supported treatments for functional dyspepsia include H. pylori eradication when infection is present, PPI therapy, low-dose tricyclic antidepressants, selected prokinetic drugs and psychological therapies. Benefits are generally modest, so matching treatment to phenotype and avoiding prolonged ineffective therapy are important. Patients with meal-triggered fullness may respond differently from those with epigastric pain or burning.

H. pylori eradication has a durable but modest benefit

In infected patients, eradication is worthwhile for cancer/ulcer prevention and can improve dyspepsia in a subset.

PPIs are useful but not universal

They provide modest benefit, particularly in epigastric burning/pain phenotypes. Lack of response should prompt a strategy change rather than indefinite escalation.

Neuromodulators and prokinetics

Low-dose TCAs have evidence for symptom improvement, especially pain-predominant disease. Prokinetics may benefit meal-related symptoms, although availability and adverse-effect profiles differ worldwide.

Behavior and diet

Avoid broad restrictive diets by default. Identify reproducible triggers, smaller meals may help, and gut-brain behavioral therapy can be valuable for persistent symptoms.

Practical clinical algorithm

Treat H. pylori if present.
Use a time-limited PPI trial.
If pain persists, consider low-dose TCA.
If postprandial fullness dominates, consider a locally available prokinetic.
Add dietitian or gut-brain behavioral support for refractory disease.
Stop ineffective therapies rather than stacking them indefinitely.

Common mistakes to avoid

Using chronic high-dose PPI after a failed trial.
Starting multiple treatments simultaneously.
Over-restricting diet and causing weight loss.
Using opioids for dyspeptic pain.
Assuming delayed emptying must be present for prokinetic benefit.

Trainee takeaway

Treatment effects are usually incremental; phenotype-guided sequential therapy is more rational than searching for one universal drug.

Frequently asked questions

Which treatment should be first?

After H. pylori management, a PPI trial is a common first pharmacologic step.

Do TCAs work only in depressed patients?

No. Their benefit relates to neuromodulation.

Should everyone get a prokinetic?

No. They are most logical in meal-related fullness/early satiety and depend on local availability and safety.

References

1. Thomson ABR. Clinical Pharmacology, Physiology and Pathophysiology: Gastroenterology, Hepatology, and Pancreaticobiliary Disorders. CAPstone Academic Publishers; 2024.

2. Thomson ABR. Practice Review in Gastroenterology. CAPstone Academic Publishers; 2014.

3. Moayyedi PM, et al. ACG and CAG Clinical Guideline: Management of Dyspepsia. Am J Gastroenterol. 2017;112:988-1013.

4. Ford AC, Mahadeva S, Carbone MF, Lacy BE, Talley NJ. Functional dyspepsia. Lancet. 2020;396:1689-1702.

Educational content only. Clinical decisions should incorporate the individual patient, local resources, product labeling, and the most current applicable guideline or regulatory information.

← Back to Clinical Questions